Tivic Health Systems Inc. has announced findings from a clinical optimization trial of its non-invasive cervical vagus nerve stimulation (ncVNS) technology, conducted in collaboration with The Feinstein Institutes for Medical Research at Northwell Health. The study demonstrated that personalizing stimulation parameters, such as frequency, amplitude, electrode positioning, and duration, significantly enhanced autonomic effects in healthy subjects. Specifically, tailoring the frequency of ncVNS to each individual led to a 46% increase in heart rate variability and was nearly nine times more effective than using a uniform frequency across all subjects. The results also indicated that optimal stimulation frequency varied between sessions and that electrode placement played a critical role in outcomes. Additionally, a four-minute stimulation period was found to be more effective than a twenty-minute session. Tivic Health stated that these results advance the understanding of neurostimulation and may have clinical utility in several patient populations. The results were announced on November 13, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101898) on November 13, 2025, and is solely responsible for the information contained therein.
Comments